E 2212
Alternative Names: E-2212Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Eisai Inc
- Class Antidementias
- Mechanism of Action Amyloid precursor protein secretase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in USA (PO)